先声药业(02096):SIM0689(PD-1/VEGF双特异性抗体)获国家药品监督管理局签发药物临床试验批准通知书

智通财经
Jun 12

智通财经APP讯,先声药业(02096)发布公告,集团自主研发的靶向PD-1/ VEGF的双特异性抗体SIM0689已获得中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书,拟开展晚期实体瘤的临床试验。

SIM0689是一种同时靶向程序性死亡受体1(PD-1)和血管内皮生长因子(VEGF)特殊表位的双特异性抗体,通过解除肿瘤细胞免疫抑制和抗血管生成,发挥强效的抗肿瘤活性。在多种人源化小鼠药效模型中,SIM0689在低剂量即展现出优异的抗肿瘤疗效,整体药效显著优于同类型分子,提示其在多种实体瘤中有广泛的应用前景。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10